Product image of Letrozol Sandoz (Letrozole) supplied by GNH India

Letrozol Sandoz

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Sandoz (Letrozole)

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy after surgery and for advanced metastatic disease. By inhibiting estrogen synthesis, letrozole reduces the hormonal stimulus that drives tumor proliferation.

GNH India supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Sandoz B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozol Sandoz, an aromatase inhibitor, is used in the management of hormone‑dependent breast cancer.

  • Hormone receptor‑positive early breast cancer: reduces risk of recurrence when given as adjuvant therapy after surgery.
  • Metastatic hormone receptor‑positive breast cancer: slows disease progression and prolongs survival.
  • Neoadjuvant setting: decreases tumor size before surgery in eligible patients.

How It Works

  • Letrozole selectively binds to the aromatase enzyme in peripheral tissues, blocking the conversion of androstenedione and testosterone into estrone and estradiol. This inhibition markedly lowers circulating estrogen concentrations, depriving estrogen‑dependent tumor cells of growth stimulation. The drug is metabolized primarily by hepatic CYP3A4 and CYP2C19 pathways, with its active metabolites contributing to the overall estrogen‑suppressive effect.

Side Effects

Letrozol Sandoz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Joint and muscle pain: arthralgia and myalgia.
  • Fatigue: persistent tiredness.
  • Nausea: mild gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Increased sweating: excessive perspiration.

Serious or Rare Side Effects

  • Severe liver injury: jaundice, elevated enzymes.
  • Bone fractures: increased risk of osteoporosis‑related breaks.
  • Deep vein thrombosis or pulmonary embolism: swelling, pain, shortness of breath.
  • Allergic reactions: rash, itching, angioedema.
  • Cardiovascular events: hypertension, myocardial infarction.

Precautions & Warnings

When prescribing Letrozol Sandoz, clinicians should observe several precautionary measures to ensure patient safety.

  • Assess bone health: monitor bone mineral density and consider calcium/vitamin D supplementation.
  • Monitor liver function: perform periodic liver enzyme tests during therapy.
  • Evaluate cardiovascular risk: watch for signs of thromboembolic events, especially in high‑risk patients.
  • Avoid use in pregnancy: contraindicated due to teratogenic risk; ensure effective contraception in women of child‑bearing potential.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Letrozol Sandoz can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Concurrent estrogen therapy: antagonizes letrozole’s estrogen‑lowering effect.
  • Strong CYP2C19 inhibitors (e.g., fluconazole, voriconazole): raise plasma concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): lower letrozole levels, reducing effectiveness.
  • Tamoxifen: may compete for metabolic pathways, altering both drugs’ activity.
  • Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring.

Frequently Asked Questions

Letrozol Sandoz is prescribed for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used in adjuvant, neoadjuvant, and metastatic settings to reduce tumor growth by lowering estrogen levels.

Letrozole works by selectively inhibiting the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. This blockade leads to a marked reduction in circulating estrogen, depriving estrogen‑dependent cancer cells of a key growth stimulus.

The specific dose of Letrozol Sandoz is determined by the prescribing physician based on the patient’s clinical condition, treatment stage, and tolerability. The prescriber will select the appropriate tablet strength and dosing schedule.

Letrozol Sandoz is classified as pregnancy category X, indicating it is contraindicated in pregnancy due to known teratogenic risk. It is also not recommended while breastfeeding, as it may pass into milk and affect the infant.

To order Letrozol Sandoz, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Sandoz (letrozole) is a third‑generation aromatase inhibitor with a long half‑life and potent estrogen suppression, similar to anastrozole and exemestane. Compared with anastrozole, letrozole often provides slightly greater estrogen reduction, which may translate into marginally improved disease control in some patients, though individual response varies.

Letrozol Sandoz tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Letrozol Sandoz is taken orally as a whole tablet, usually once daily. It can be taken with or without food, but patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe liver injury, osteoporosis‑related bone fractures, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should report signs of jaundice, unexplained bone pain, swelling of the limbs, or sudden shortness of breath to their physician promptly.

Letrozol Sandoz should not be used by pregnant or breastfeeding women, premenopausal women, patients with severe hepatic impairment, or anyone with known hypersensitivity to letrozole or any of the tablet excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT